539 related articles for article (PubMed ID: 34387172)
1. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Shahrbaf MA; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
[TBL] [Abstract][Full Text] [Related]
2. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O; Lai WF
Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
4. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
[TBL] [Abstract][Full Text] [Related]
5. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
[No Abstract] [Full Text] [Related]
8. Remdesivir for patients with COVID-19.
Wu PE; Morris AM
CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097
[No Abstract] [Full Text] [Related]
9. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M
Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175
[TBL] [Abstract][Full Text] [Related]
10. An effective drug against COVID-19: reality or dream?
Yaghoubi A; Amel Jamehdar S; Movaqar A; Milani N; Soleimanpour S
Expert Rev Respir Med; 2021 Apr; 15(4):505-518. PubMed ID: 33215942
[No Abstract] [Full Text] [Related]
11. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma.
Ramzy S; Abdelazim AH; Osman AO; Hasan MA
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Nov; 281():121625. PubMed ID: 35863184
[TBL] [Abstract][Full Text] [Related]
12. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
Shohan M; Nashibi R; Mahmoudian-Sani MR; Abolnezhadian F; Ghafourian M; Alavi SM; Sharhani A; Khodadadi A
Eur J Pharmacol; 2022 Jan; 914():174615. PubMed ID: 34863994
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir for the treatment of COVID-19 in pregnancy.
Lampejo T
J Med Virol; 2021 Jul; 93(7):4114-4119. PubMed ID: 33788273
[No Abstract] [Full Text] [Related]
15. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of the antiviral drug remdesivir: An update.
Fan Q; Zhang B; Ma J; Zhang S
Biomed Pharmacother; 2020 Oct; 130():110532. PubMed ID: 32707440
[No Abstract] [Full Text] [Related]
18. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Lai CC; Chao CM; Hsueh PR
J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Wu PE; Morris AM
CMAJ; 2021 Apr; 193(14):E495-E496. PubMed ID: 33824151
[No Abstract] [Full Text] [Related]
20. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
